A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer

PHASE3TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

October 31, 2019

Study Completion Date

October 31, 2019

Conditions
Stage III (IIIB or IIIC) Colon Cancer
Interventions
DRUG

Regorafenib

3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles

DRUG

Placebo

3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles

Trial Locations (51)

15212

Allegheny General Hospital, Pittsburgh

15232

UPMC Cancer Centers, Pittsburgh

18510

Scranton Hematology Oncology, Scranton

18840

Guthrie Medical Group, PC, Sayre

19001

Abington Hospital -Jefferson South, Abington

19107

Thomas Jefferson University Hospital, Philadelphia

19611

Reading Hospital - McGlinn Cancer Institute, West Reading

23298

Virginia Commonwealth University, Richmond

26506

West Virginia University, Morgantown

27157

Wake Forest Baptist Health, Winston-Salem

27511

Waverly Hematology Oncology, Cary

28054

CaroMont Regional Medical Center, Gastonia

28374

First Health of the Carolinas Cancer Center, Pinehurst

28791

Margaret R. Pardee Memorial Hospital, Hendersonville

29502

McLeod Cancer Center for Treatment and Research, Florence

29621

AnMed Health Cancer Center, Anderson

31404

Memorial Health University Medical Center, Savannah

32610

University of Florida, Gainesville

33140

Mount Sinai Comprehensive Cancer Center, Miami Beach

37660

Wellmont Medical Associates Oncology and Hematology, Kingsport

37916

Thompson Cancer Survival Center, Knoxville

40202

Norton Cancer Institute, Norton Healthcare Pavilion, Louisville

43210

James Cancer Hospital and Solove Research Institute at the Ohio State University Comprehensive Cancer Center, Columbus

43623

Toledo Clinic Cancer Center, Toledo

46628

Northern Indiana Cancer Research Consortium, South Bend

48910

Breslin Cancer Center, Lansing

50702

Covenant Cancer Treatment Center, Waterloo

52242

University of Iowa, Iowa City

52403

Oncology Associates at Mercy Medical Center, Cedar Rapids

52804

Genesis Medical Center - West Campus, Davenport

54301

Green Bay Oncology, Ltd. - St. Vincent Hospital, Green Bay

55416

Metro Minnesota Community Oncology Research Consortium, Saint Louis Park

61801

Carle Cancer Center, Urbana

62526

Cancer Care Specialists of Illinois - Decatur Memorial Hospital, Decatur

68106

Missouri Valley Cancer Consortium, Omaha

70112

Tulane University Health Sciences Center, New Orleans

79410

Joe Arrington Cancer Research and Treatment Center, Lubbock

80222

Colorado Cancer Research Program, Denver

89106

Nevada Cancer Research Foundation, Inc., Las Vegas

92868

St. Joseph Hospital of Orange, Orange

94589

Kaiser Permanente Medical Center - Vallejo, Vallejo

95403

St. Joseph Heritage Healthcare, Santa Rosa

06510

Yale University, New Haven

60540-7499

Edward Hospital Cancer Center, Naperville

04074

New England Cancer Specialists, Scarborough

01201

Berkshire Medical Center Cancer and Infusion Center, Pittsfield

08103

MD Anderson Cancer Center at Cooper, Camden

07740-6395

Monmouth Medical Center, Long Branch

07112

Newark Beth Israel Medical Center, Newark

08755

Community Medical Center, Toms River

17033-0850

Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

NSABP Foundation Inc

NETWORK